CIIE Stories | Growth record of 'CIIE baby'

For seven consecutive years, each appearance at the CIIE has been marked by a distinct new identity—this is the story of Dupilumab Injection(Dupixent®) from the multinational pharmaceutical company Sanofi.

From enhancing disease awareness to being approved in China two years ahead of schedule and included in the national health insurance, from expanding indications for atopic dermatitis to covering all age groups, and to entering the respiratory disease treatment field—this innovative drug has continuously evolved on the stage of the CIIE.

It has grown from a"CIIE baby" to a"Hexagonal Warrior" covering seven major indications. This is a testament to global innovation accelerating its landing in China and evidence that China's speed has surpassed global benchmarks.

Please watch this episode of“CIIE Stories” and hear the firsthand experiences of Paul Hudson, CEO of Sanofi; Wayne Shi, President of Sanofi Greater China; Jian Li, Medical Head of Sanofi China Specialty Care, and Xian Ji, General Manager of Sanofi China Specialty Care.